Lab No. : 1011904230054 Reg No.

: 1439860
Patient Name : Mr. UDAY BHAN SINGH Reg. Date : 23/Apr/2019 11:00AM
Client Name:Prabhu Pathology, Kanpur, Client Code:1181, Address:3a ratanlal nagar kanpur up, Mobile:8081185656

Age/Sex : 54 Y / Male Sample Coll. Date : 23/Apr/2019 02:52PM

Barcode No : 4306778 Sample Rec. Date : 23/Apr/2019
Referred By : Dr. C K TALREJA Approved Date : 24/Apr/2019 10:36AM
Ref. Source : Panel : Prabhu Pathology, Kanpur
Test Name Observation Value Unit Bio. Ref. Interval

IMMUNOLOGY - SEROLOGY

HEPATITIS B SURFACE ANTIGEN (ELISA/CMIA)

SampleType:Serum
HEPATITIS B SURFACE ANTIGEN 4498.82 S/CO <1 - Non Reactive
by CMIA >1 - Reactive

COMMENTS:
-HBsAg is the first serological marker after infection with Hepatitis B Virus appearing one to ten weeks after exposure
and two to eight weeks before the onset of clinical symptoms. HBsAg persists during the acute phase and clears late in
the convalescence phase. Failure to clear HBsAg within six months indicates a chronic HBsAg carrier state. HBsAg assays
are used to identify the persons infected with HBV and to prevent transmission of the virus by blood and blood products
as well as to monitor the status of infected individuals in combination with other hepatitis B serological markers.
-Borderline cases must be confirmed with confirmatory neutralizing assay.

LIMITATIONS:
-Results should be used in conjunction with patient history and other hepatitis markers for diagnosis of acute and chronic
infections.
-Specimens from patients who have received preparations of mouse monoclonal antibodies for diagnosis or therapy may
contain human anti-mouse antibodies (HAMA) which may produce anomalous values when tested with assay kits that
employs mouse monoclonal antibodies.
-Heterophilic antibodies in human serum can react with reagent immunoglobulins, interfering with in vitro immunoassays.
Patients routinely exposed to animals or animal serum products can be prone to this interference and anomalous
results may be observed.
-Cross reactivity for specimens from individual with medical conditions (Pregnancy, HIV etc) has been observed.
-HBsAg mutations may result in a false negative result in some HBsAg assays.
-If HBsAg results are inconsistent with clinical evidence, additional testing is suggested to confirm the result.

REMARK: Test was repeated with HBsAg qualitative rapid card and found to be reactive.

*** End Of Report ***

Page 1 of 1